Breaking News

WuXi PharmaTech Begins HPAPI Ops

May 28, 2014

Adds HPAPI processing capabilities at Shanghai lab

WuXi PharmaTech’s manufacturing subsidiary, Syn-The-All Pharmaceutical Co., Ltd. (STA), has begun operations for a high-potency active pharmaceutical ingredient (HPAPI) at its lab in Shanghai. The lab has added HPAPI processing to its portfolio of services to support process development and clinical trial supply of high-potency small molecules at kilogram scale.
 
"With the increasing use of HPAPIs in drug discovery and development, this new service augments WuXi's ability to provide highly efficient and cost-effective solutions for our partners worldwide," said Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech.

Related Contract Manufacturing:

blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.